Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03494231 | A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 5 | Henlix, IncINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02160041 | BGJ398 for Patients With Tumors With FGFR Genetic Alterations(CBGJ398XUS04) | terminated | Phase 2 | 84 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT02548390 | Study of Intravenous RXDX-107 in Patients With Solid Tumors | terminated | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 1 | Apr 25, 2019 | clinicaltrials |
| NCT00003194 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | terminated | Phase 1 | 24 | Seattle Children's HospitalOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01431534 | A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) | terminated | Phase 1 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02070406 | Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00814463 | Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases | terminated | Phase 2 | 1 | Duke UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01284335 | A Safety Study in Participants With Advanced Solid Tumors | terminated | Phase 1 | 234 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | terminated | Phase 1 | 53 | MedImmune LLCINDUSTRY | 3 | Dec 19, 2018 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 14 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02472977 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors(CXCessoR4) | terminated | Phase 1 / Phase 2 | 61 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2018 | clinicaltrials |
| NCT02508441 | Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors | terminated | Phase 1 | 22 | Andes BiotechnologiesINDUSTRY | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03320525 | Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)(CHITIN) | terminated | Phase 1 | 11 | Herlev HospitalOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00742105 | Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01234922 | Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors | terminated | Phase 2 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01463696 | Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) | terminated | Phase 1 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02492477 | TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients | terminated | Phase 1 | 4 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01907802 | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 2 | Aug 14, 2018 | clinicaltrials |
| NCT01804530 | Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors | terminated | Phase 1 | 59 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02673736 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | terminated | Phase 1 | 11 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01378377 | Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus | terminated | Phase 1 | 33 | EMD SeronoINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | terminated | Phase 1 | 10 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01705106 | Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies | terminated | Phase 1 | 21 | University of ChicagoOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02269111 | Quantitative MRI in Assessing Disease in Patients With Brain Tumors | terminated | N/A | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 29, 2018 | clinicaltrials |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT01904916 | CPCT-05 Biopsy Protocol Patient Selection | terminated | N/A | 195 | P.O. WitteveenOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02243917 | A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 62 | Cleave Biosciences, Inc.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT01822756 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | terminated | Phase 1 | 42 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00095862 | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | terminated | Phase 1 / Phase 2 | 24 | Wiseman Research Initiatives LLCINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01668550 | A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours(AZD0424) | terminated | Phase 1 | 43 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT02228811 | A Study of DCC-2701 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 44 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | terminated | Phase 1 | 5 | Incyte CorporationINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00470548 | Abraxane and Alimta in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00807755 | Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors | terminated | Phase 1 | 5 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02593708 | Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | terminated | Phase 1 | 6 | Michelle MeliskoOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 4 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01581541 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment | terminated | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2017 | clinicaltrials |
| NCT02100007 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | MEI Pharma, Inc.INDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01302405 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 23 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02653196 | A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | terminated | Early Phase 1 | 1 | Montefiore Medical CenterOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00695448 | Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma | terminated | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Jul 25, 2017 | clinicaltrials |
| NCT01632696 | Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors | terminated | Early Phase 1 | 11 | Peregrine PharmaceuticalsINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2019source: clinicaltrials